

CITATION REPORT

List of articles citing

Antimicrobial therapy in critically ill patients: a review of pathophysiological conditions responsible for altered disposition and pharmacokinetic variability

DOI: 10.2165/00003088-200544100-00002
Clinical Pharmacokinetics, 2005, 44, 1009-34.

Source: <https://exaly.com/paper-pdf/39421319/citation-report.pdf>

Version: 2024-04-25

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
248	Ceftazidime in acute myeloid leukemia patients with febrile neutropenia: helpfulness of continuous intravenous infusion in maximizing pharmacodynamic exposure. <i>Antimicrobial Agents and Chemotherapy</i> , 2005 , 49, 3550-3	5.9	41
247	Consider possible changes in the pharmacokinetic properties of antibacterials when treating the critically ill. 2006 , 22, 21-23		
246	Treatment of <i>Pseudomonas aeruginosa</i> infection in critically ill patients. 2006 , 4, 639-62		13
245	Pharmacokinetic-pharmacodynamic aspects of antimicrobial prophylaxis with teicoplanin in patients undergoing major vascular surgery. 2006 , 27, 15-9		3
244	Efficacy of the combination of levofloxacin plus ceftazidime in the treatment of hospital-acquired pneumonia in the intensive care unit. 2006 , 28, 582-5		2
243	Hospital-acquired pneumonia in the 21st century: a review of existing treatment options and their impact on patient care. 2006 , 7, 1555-69		17
242	Antibacterial dosage in intensive-care-unit patients based on pharmacokinetic/pharmacodynamic principles. 2006 , 12, 477-82		9
241	Use of in vitro critical inhibitory concentration, a novel approach to predict in vivo synergistic bactericidal effect of combined amikacin and piperacillin against <i>Pseudomonas aeruginosa</i> in a systemic rat infection model. 2006 , 23, 729-41		9
240	Hyperlactacidemia potentially due to linezolid overexposure in a liver transplant recipient. 2006 , 42, 434-5		62
239	Pharmacokinetics of unbound linezolid in plasma and tissue interstitium of critically ill patients after multiple dosing using microdialysis. <i>Antimicrobial Agents and Chemotherapy</i> , 2006 , 50, 2455-63	5.9	91
238	The antimicrobial therapy puzzle: could pharmacokinetic-pharmacodynamic relationships be helpful in addressing the issue of appropriate pneumonia treatment in critically ill patients?. 2006 , 42, 1764-71		111
237	Ideal microbiological and pharmacological characteristics of a quality antimicrobial agent: comparing original and generic molecules. 2007 , 19, 609-19		3
236	Drug dosing in continuous renal replacement therapy: general rules. 2007 , 13, 645-51		87
235	Linezolid cerebrospinal fluid concentration in central nervous system infection. 2007 , 19, 90-3		15
234	[Treatment of a septic shock due to multiresistant <i>Acinetobacter baumannii</i> with tigecycline in combination]. 2007 , 26, 1056-8		10
233	Ertapenem: the new carbapenem 5 years after first FDA licensing for clinical practice. 2007 , 8, 237-56		39
232	Pharmacodynamics of antibiotics to treat multidrug-resistant Gram-positive hospital infections. 2007 , 5, 255-70		13

231	Use of pharmacodynamic principles to optimise dosage regimens for antibacterial agents in the elderly. 2007 , 24, 275-92		18
230	Pharmacokinetic and pharmacodynamic aspects of antibiotic use in high-risk populations. 2007 , 21, 821-46, x		19
229	Factors influencing caspofungin plasma concentrations in patients of a surgical intensive care unit. <i>Journal of Antimicrobial Chemotherapy</i> , 2007 , 60, 100-6	5.1	96
228	Pharmacokinetic considerations for antimicrobial therapy in patients receiving renal replacement therapy. <i>Clinical Pharmacokinetics</i> , 2007 , 46, 997-1038	6.2	137
227	Pharmacokinetics and pharmacodynamics of levofloxacin in critically ill patients with ventilator-associated pneumonia. 2007 , 30, 162-8		28
226	Optimal management of urosepsis from the urological perspective. 2007 , 30, 390-7		47
225	Clearance of levofloxacin by an in vitro model of continuous venovenous hemodialysis (CVVHD). 2007 , 30, 889-95		4
224	Limiting the attributable mortality of nosocomial infection and multidrug resistance in intensive care units. 2008 , 14, 5-13		59
223	Therapeutic challenges of urosepsis. 2008 , 38 Suppl 2, 45-9		65
222	[Recommendations for antibiotic monitoring in ICU patients]. 2008 , 32, 113-23		1
221	Should the currently recommended twice-daily dosing still be considered the most appropriate regimen for treating MRSA ventilator-associated pneumonia with vancomycin?. <i>Clinical Pharmacokinetics</i> , 2008 , 47, 147-52	6.2	25
220	Population pharmacokinetics of meropenem in critically ill patients undergoing continuous renal replacement therapy. <i>Clinical Pharmacokinetics</i> , 2008 , 47, 173-80	6.2	48
219	Clinical relevance of pharmacokinetics and pharmacodynamics in cardiac critical care patients. <i>Clinical Pharmacokinetics</i> , 2008 , 47, 449-62	6.2	23
218	Linezolid pharmacokinetic/pharmacodynamic profile in critically ill septic patients: intermittent versus continuous infusion. 2008 , 31, 122-9		125
217	[Indications and uses of neuromuscular blocking agents in the ICU]. 2008 , 27, 567-73		4
216	[Recommendations for antibiotic monitoring in ICU patients]. 2008 , 26, 230-9		6
215	Pharmacokinetics/pharmacodynamics of antibacterials in the Intensive Care Unit: setting appropriate dosing regimens. 2008 , 32, 294-301		75
214	[Nosocomial infection indicators]. 2008 , 131 Suppl 3, 48-55		5

213	Effect of severity disease on the pharmacokinetics of cefuroxime in children with multiple organ system failure. 2008 , 31, 316-20		5
212	Antimicrobial dosing strategies in critically ill patients with acute kidney injury and high-dose continuous veno-venous hemofiltration. 2008 , 14, 654-9		25
211	Glomerular hyperfiltration and albuminuria in critically ill patients. 2008 , 36, 674-80		70
210	Prospectively validated dosing nomograms for maximizing the pharmacodynamics of vancomycin administered by continuous infusion in critically ill patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2009 , 53, 1863-7	5.9	104
209	Plasma and peritoneal concentration following continuous infusion of cefotaxime in patients with secondary peritonitis. <i>Journal of Antimicrobial Chemotherapy</i> , 2009 , 63, 564-7	5.1	26
208	Tissue accumulation of cephalothin in burns: a comparative study by microdialysis of subcutaneous interstitial fluid cephalothin concentrations in burn patients and healthy volunteers. <i>Antimicrobial Agents and Chemotherapy</i> , 2009 , 53, 210-5	5.9	11
207	Antimicrobial dosing concepts and recommendations for critically ill adult patients receiving continuous renal replacement therapy or intermittent hemodialysis. 2009 , 29, 562-77		123
206	Experimental non-alcoholic fatty liver disease results in decreased hepatic uptake transporter expression and function in rats. 2009 , 613, 119-27		82
205	Population pharmacokinetic analysis of vancomycin in patients with gram-positive infections and the influence of infectious disease type. 2009 , 34, 473-83		52
204	Bench-to-bedside review: Appropriate antibiotic therapy in severe sepsis and septic shock--does the dose matter?. 2009 , 13, 214		127
203	[Aminoglycosides and polymyxins]. 2009 , 27, 178-88		4
202	Variations in MIC value caused by differences in experimental protocol. 2009 , 79, 44-7		33
201	Pharmacokinetics of once-daily dosing of ertapenem in critically ill patients with severe sepsis. 2009 , 33, 432-6		58
200	Penetration of Antibacterials into Bone. <i>Clinical Pharmacokinetics</i> , 2009 , 48, 125-127	6.2	13
199	Antimicrobial agents for surgical infections. 2009 , 89, 327-47, vii		3
198	Cardiac surgery patients may have clinically relevant changes in the pharmacokinetics of frequently used drugs. 2009 , 25, 23-26		
197	Appropriate use of antimicrobials: the peculiarity of septic patients. 2009 , 34 Suppl 4, S52-4		2
196	Occult knee effusions in the intensive care environment identified by ultrasound: a new third space?. 2009 , 15, 408-10		

195	Population pharmacokinetic modeling and optimal sampling strategy for Bayesian estimation of amikacin exposure in critically ill septic patients. <i>Therapeutic Drug Monitoring</i> , 2010 , 32, 749-56	3.2	548
194	Diagnosis and management of complicated intra-abdominal infection in adults and children: guidelines by the Surgical Infection Society and the Infectious Diseases Society of America. 2010 , 50, 133-64		974
193	Pharmacokinetics of linezolid in septic patients with and without extended dialysis. 2010 , 66, 291-8		53
192	Pharmacokinetics of moxifloxacin in patients with severe sepsis or septic shock. 2010 , 36, 979-83		23
191	Antifungal Dosing in Critically Ill Patients. 2010 , 4, 78-86		3
190	Empirical models for dosage optimization of four beta-lactams in critically ill septic patients based on therapeutic drug monitoring of amikacin. 2010 , 43, 589-98		17
189	Interpreting culture and susceptibility data in critical care: perks and pitfalls. 2010 , 20, 110-31		10
188	How to manage medications in the setting of liver disease with the application of six questions. 2010 , 64, 858-67		7
187	Vancomycin dosing assessment in intensive care unit patients based on a population pharmacokinetic/pharmacodynamic simulation. 2010 , 70, 201-12		71
186	Initial vancomycin dosing recommendations for critically ill patients undergoing continuous venovenous hemodialysis. 2010 , 63, 196-206		11
185	The role of admission surveillance cultures in patients requiring prolonged mechanical ventilation in the intensive care unit. 2010 , 38, 325-35		18
184	Daily serum piperacillin monitoring is advisable in critically ill patients. 2010 , 35, 500-3		41
183	Pharmacological issues of linezolid: an updated critical review. <i>Clinical Pharmacokinetics</i> , 2010 , 49, 439-47.2		68
182	Management of aminoglycosides in the intensive care unit. 2010 , 25, 327-42		23
181	Revisiting the loading dose of amikacin for patients with severe sepsis and septic shock. 2010 , 14, R53		139
180	Insufficient β -lactam concentrations in the early phase of severe sepsis and septic shock. 2010 , 14, R126		242
179	Diagnosis and management of complicated intra-abdominal infection in adults and children: guidelines by the Surgical Infection Society and the Infectious Diseases Society of America. 2010 , 11, 79-109		316
178	[Antimicrobial blood concentrations in burns. A five years retrospective survey]. 2010 , 58, 137-43		2

177	High cefepime plasma concentrations and neurological toxicity in febrile neutropenic patients with mild impairment of renal function. <i>Antimicrobial Agents and Chemotherapy</i> , 2010 , 54, 4360-7	5.9	107
176	Recommended β -lactam regimens are inadequate in septic patients treated with continuous renal replacement therapy. 2011 , 15, R137		153
175	Antibiotics in critically ill patients: a systematic review of the pharmacokinetics of β -lactams. 2011 , 15, R206		239
174	Effect of fluid loading during hypovolaemic shock on caspofungin pharmacokinetic parameters in pig. 2011 , 15, R219		5
173	Vancomycin clearance during continuous venovenous haemofiltration in critically ill patients. 2011 , 38, 152-6		34
172	Urosepsis--from the view of the urologist. 2011 , 38 Suppl, 51-7		56
171	Year in review 2010: Critical Care--Infection. 2011 , 15, 238		7
170	Kill rate of mastitis pathogens by a combination of cefalexin and kanamycin. 2011 , 110, 184-90		8
169	Antimicrobial susceptibility of Salmonella isolates recovered from calves with diarrhoea in Australia. 2011 , 89, 402-8		19
168	Early Adequate Antibiotic Therapy. 2011 , 305-313		
167	Appropriate antibiotic dosage levels in the treatment of severe sepsis and septic shock. <i>Current Infectious Disease Reports</i> , 2011 , 13, 406-15	3.9	23
166	WSES consensus conference: Guidelines for first-line management of intra-abdominal infections. 2011 , 6, 2		51
165	Optimizing ciprofloxacin dosing in intensive care unit patients through the use of population pharmacokinetic-pharmacodynamic analysis and Monte Carlo simulations. <i>Journal of Antimicrobial Chemotherapy</i> , 2011 , 66, 1798-809	5.1	35
164	Assessment of interindividual variability of plasma concentrations after administration of high doses of intravenous amoxicillin or cloxacillin in critically ill patients. 2011 , 23, 277-81		11
163	Simultaneous determination of 12 beta-lactam antibiotics in human plasma by high-performance liquid chromatography with UV detection: application to therapeutic drug monitoring. <i>Antimicrobial Agents and Chemotherapy</i> , 2011 , 55, 4873-9	5.9	103
162	Pharmacodynamics of empirical antibiotic monotherapies for an intensive care unit (ICU) population based on Canadian surveillance data. <i>Journal of Antimicrobial Chemotherapy</i> , 2011 , 66, 343-9	5.1	40
161	Micafungin concentrations in the plasma and burn eschar of severely burned patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2012 , 56, 1113-5	5.9	16
160	Overton's rule helps to estimate the penetration of anti-infectives into patients' cerebrospinal fluid. <i>Antimicrobial Agents and Chemotherapy</i> , 2012 , 56, 979-88	5.9	13

159	Antibiotic therapy in hematological neutropenic patients: what is the news?. 2012 , 1, S20-1		
158	Pharmacokinetic and pharmacodynamic issues for antimicrobial therapy in patients with cancer. 2012 , 54, 1785-92		48
157	Dosing nomograms for attaining optimum concentrations of meropenem by continuous infusion in critically ill patients with severe gram-negative infections: a pharmacokinetics/pharmacodynamics-based approach. <i>Antimicrobial Agents and Chemotherapy</i> , 2012 , 56, 6343-8	5.9	61
156	Antibiotic strategy in severe community-acquired pneumococcal pneumonia. 2012 , 42, 226-34		1
155	DALI: Defining Antibiotic Levels in Intensive care unit patients: a multi-centre point of prevalence study to determine whether contemporary antibiotic dosing for critically ill patients is therapeutic. 2012 , 12, 152		34
154	Antimicrobial use in horses undergoing colic surgery. 2012 , 26, 1449-56		24
153	Management of antimicrobial use in the intensive care unit. 2012 , 72, 447-70		14
152	How to optimise antimicrobial prescriptions in the Intensive Care Unit: principles of individualised dosing using pharmacokinetics and pharmacodynamics. 2012 , 39, 187-92		45
151	Decreased meropenem levels in Intensive Care Unit patients with augmented renal clearance: benefit of therapeutic drug monitoring. 2012 , 40, 370-2		50
150	Pharmacokinetics of beta-lactam antibiotics in patients with intra-abdominal disease: a structured review. 2012 , 13, 9-17		16
149	Simple approach to improving vancomycin dosing in intensive care: a standardised loading dose results in earlier therapeutic levels. <i>Internal Medicine Journal</i> , 2012 , 42, 23-9	1.6	45
148	Risk factors for voriconazole hepatotoxicity at 12 weeks in lung transplant recipients. 2012 , 12, 1929-35		37
147	Correlation of pharmacokinetic/pharmacodynamic-derived predictions of antibiotic efficacy with clinical outcomes in severely ill patients with <i>Pseudomonas aeruginosa</i> pneumonia. 2013 , 33, 1022-34		6
146	A research agenda on the management of intra-abdominal candidiasis: results from a consensus of multinational experts. 2013 , 39, 2092-106		138
145	Approaches for dosage individualisation in critically ill patients. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2013 , 9, 1481-93	5.5	8
144	The clinical relevance of plasma protein binding changes. <i>Clinical Pharmacokinetics</i> , 2013 , 52, 1-8	6.2	173
143	Vancomycin pharmacodynamics and survival in patients with methicillin-resistant <i>Staphylococcus aureus</i> -associated septic shock. 2013 , 41, 255-60		87
142	Amikacin population pharmacokinetics in critically ill Kuwaiti patients. 2013 , 2013, 202818		10

141	Pharmacokinetics of meropenem in critically ill patients with severe infections. <i>Therapeutic Drug Monitoring</i> , 2013 , 35, 63-70	3.2	33
140	Diagnosis and management for urosepsis. 2013 , 20, 963-70		90
139	Reply to "Breakthrough bacteremia by linezolid-susceptible <i>Enterococcus faecalis</i> under linezolid treatment in a severe polytrauma patient". <i>Antimicrobial Agents and Chemotherapy</i> , 2013 , 57, 6413-4	5.9	
138	Optimal doripenem dosing simulations in critically ill nosocomial pneumonia patients with obesity, augmented renal clearance, and decreased bacterial susceptibility. 2013 , 41, 489-95		65
137	Vancomycin intermittent dosing versus continuous infusion for treatment of ventilator-associated pneumonia in trauma patients. 2013 , 79, 1185-90		20
136	The effect of pathophysiology on pharmacokinetics in the critically ill patient--concepts appraised by the example of antimicrobial agents. 2014 , 77, 3-11		242
135	Pharmacokinetics of a polyene antifungal agent, liposomal amphotericin B (L-AMB), in a severely burned patient. 2014 , 26, 312-4		3
134	Variability of linezolid concentrations after standard dosing in critically ill patients: a prospective observational study. 2014 , 18, R148		75
133	PK/PD of Oxazolidinones. 2014 , 401-443		
132	Quantification of linezolid in serum by LC-MS/MS using semi-automated sample preparation and isotope dilution internal standardization. 2014 , 52, 381-9		18
131	Optimizing antimicrobial therapy in critically ill patients. 2014 , 7, 261-71		12
130	Bugs, hosts and ICU environment: countering pan-resistance in nosocomial microbiota and treating bacterial infections in the critical care setting. 2014 , 61, e1-e19		4
129	Penetration of micafungin into the burn eschar in patients with severe burns. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 2014 , 39, 93-7	2.7	7
128	The influence of acute kidney injury on antimicrobial dosing in critically ill patients: are dose reductions always necessary?. 2014 , 79, 77-84		43
127	Insufficient fluconazole exposure in pediatric cancer patients and the need for therapeutic drug monitoring in critically ill children. 2014 , 59, 1527-33		22
126	Optimized dosing of cefazolin in patients treated with nocturnal home hemodialysis. 2014 , 64, 479-80		3
125	Pharmacokinetics of vancomycin in critically ill patients undergoing continuous venovenous haemodialysis. 2014 , 44, 367-8		2
124	[Pharmacokinetic and pharmacodynamic aspects in antibiotic treatment]. 2014 , 109, 162-6		3

123	Predictors of insufficient amikacin peak concentration in critically ill patients receiving a 25 mg/kg total body weight regimen. 2014 , 40, 998-1005	76
122	Population pharmacokinetics of imipenem in critically ill patients with suspected ventilator-associated pneumonia and evaluation of dosage regimens. 2014 , 78, 1022-34	22
121	Emerging approaches to the treatment of ventilator-associated pneumonia. 2014 , 4, 343-359	
120	Urosepsis: Overview of the Diagnostic and Treatment Challenges. 2015 , 3,	22
119	Implications of Augmented Renal Clearance on Drug Dosing in Critically Ill Patients: A Focus on Antibiotics. 2015 , 35, 1063-75	73
118	Determination of Optimal Amikacin Dosing Regimens for Pediatric Patients With Burn Wound Sepsis. 2015 , 36, e244-52	20
117	Antibiotic dose optimization in critically ill patients. 2015 , 39, 563-572	1
116	First-dose pharmacokinetics of aminoglycosides in critically ill haematological malignancy patients. 2015 , 45, 46-53	14
115	Antimicrobial Use in the Critical Care Patient. 2015 , 918-927	2
114	Teicoplanin use in adult patients with haematological malignancy: Exploring relationships between dose, trough concentrations, efficacy and nephrotoxicity. 2015 , 46, 406-12	23
113	Antibiotic dose optimization in critically ill patients. 2015 , 39, 563-72	27
112	Suboptimal antimicrobial drug exposure in patients with renal impairment. 2015 , 37, 906-16	2
111	Population pharmacokinetics of single-dose amikacin in critically ill patients with suspected ventilator-associated pneumonia. 2015 , 71, 75-83	26
110	Urosepsis: Overview of the Diagnostic and Treatment Challenges. 2016 , 135-157	
109	Special Issues in Therapeutic Drug Monitoring in Patients With Uremia, Liver Disease, and in Critically Ill Patients. 2016 , 245-260	4
108	CONSIDERACIONES FARMACOLÓGICAS GENERALES Y PARTICULARES EN CUIDADOS INTENSIVOS. 2016 , 27, 636-645	
107	Pharmacokinetic/pharmacodynamic evaluation of linezolid for the treatment of staphylococcal infections in critically ill patients. 2016 , 48, 259-64	16
106	Pharmacokinetics of Cefepime in Patients with Cancer and Febrile Neutropenia in the Setting of Hematologic Malignancies or Hematopoietic Cell Transplantation. 2016 , 36, 1003-10	4

105	Switching From Intermittent to Continuous Infusion of Vancomycin in Critically Ill Patients: Toward a More Robust Exposure. <i>Therapeutic Drug Monitoring</i> , 2016 , 38, 398-401	3.2	11
104	Population pharmacokinetics of arbekacin in different infectious disease settings and evaluation of dosing regimens. 2016 , 22, 436-43		3
103	Influence of Renal Replacement Modalities on Amikacin Population Pharmacokinetics in Critically Ill Patients on Continuous Renal Replacement Therapy. <i>Antimicrobial Agents and Chemotherapy</i> , 2016 , 60, 4901-9	5.9	19
102	Variations of pharmacokinetics of drugs in patients with cirrhosis. 2016 , 9, 441-58		11
101	Amikacin in Critically Ill Patients: A Review of Population Pharmacokinetic Studies. <i>Clinical Pharmacokinetics</i> , 2017 , 56, 127-138	6.2	39
100	Population pharmacokinetics of teicoplanin and attainment of pharmacokinetic/pharmacodynamic targets in adult patients with haematological malignancy. 2017 , 23, 674.e7-674.e13		15
99	Substantial Impact of Altered Pharmacokinetics in Critically Ill Patients on the Antibacterial Effects of Meropenem Evaluated via the Dynamic Hollow-Fiber Infection Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2017 , 61,	5.9	20
98	[Personalised pharmacotherapy in intensive care unit patients]. 2017 , 112, 289-294		1
97	[Prudent use of antimicrobial prophylaxis : Prevention of increasing antibiotic resistance]. 2017 , 56, 1109-1115		3
96	Clinical on-site monitoring of β -lactam antibiotics for a personalized antibiotherapy. 2017 , 7, 3127		15
95	Optimizing β -lactams treatment in critically-ill patients using pharmacokinetics/pharmacodynamics targets: are first conventional doses effective?. 2017 , 15, 677-688		45
94	Variability in Trough Total and Unbound Teicoplanin Concentrations and Achievement of Therapeutic Drug Monitoring Targets in Adult Patients with Hematological Malignancy. <i>Antimicrobial Agents and Chemotherapy</i> , 2017 , 61,	5.9	15
93	Impact of β -lactam antibiotic therapeutic drug monitoring on dose adjustments in critically ill patients undergoing continuous renal replacement therapy. 2017 , 49, 589-594		34
92	Highly Sensitive Broadband Raman Sensing of Antibiotics in Step-Index Hollow-Core Photonic Crystal Fibers. 2017 , 4, 138-145		61
91	Influence of Mechanical Ventilation on the Pharmacokinetics of Vancomycin Administered by Continuous Infusion in Critically Ill Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2017 , 61,	5.9	14
90	Management of multidrug-resistant <i>Pseudomonas aeruginosa</i> in the intensive care unit: state of the art. 2017 , 15, 861-871		36
89	Low Caspofungin Exposure in Patients in Intensive Care Units. <i>Antimicrobial Agents and Chemotherapy</i> , 2017 , 61,	5.9	29
88	High target attainment for β -lactam antibiotics in intensive care unit patients when actual minimum inhibitory concentrations are applied. 2017 , 36, 553-563		11

87	Pharmacokinetics of ceftiofur in healthy and lipopolysaccharide-induced endotoxemic newborn calves treated with single and combined therapy. 2017 , 79, 1245-1252		3
86	Therapeutic Drug Monitoring of Beta-Lactams and Other Antibiotics in the Intensive Care Unit: Which Agents, Which Patients and Which Infections?. 2018 , 78, 439-451		63
85	Pharmacokinetic and Pharmacodynamic Considerations of Antibiotics of Last Resort in Treating Gram-Negative Infections in Adult Critically Ill Patients. <i>Current Infectious Disease Reports</i> , 2018 , 20, 10	3.9	5
84	Population pharmacokinetics of total and unbound teicoplanin concentrations and dosing simulations in patients with haematological malignancy. <i>Journal of Antimicrobial Chemotherapy</i> , 2018 , 73, 995-1003	5.1	16
83	Antibiotic Use in the Intensive Care Unit: Optimization and De-Escalation. 2018 , 33, 647-655		39
82	[Dose adjustment of anti-infective drugs in patients with renal failure and renal replacement therapy in intensive care medicine : Recommendations from the renal section of the DGIIN, OIAIN and DIVI]. 2018 , 113, 384-392		2
81	Intracellular Pharmacokinetics of Antibacterials and Their Clinical Implications. <i>Clinical Pharmacokinetics</i> , 2018 , 57, 177-189	6.2	17
80	Continuous Infusion Versus Intermittent Bolus of Beta-Lactams in Critically Ill Patients with Respiratory Infections: A Systematic Review and Meta-analysis. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 2018 , 43, 155-170	2.7	23
79	Physiological Manifestations of Critical Illness. 2018 , 31-46		0
78	Implication of Haemodiafiltration Flow Rate on Amikacin Pharmacokinetic Parameters in Critically Ill Patients. 2018 , 45, 88-94		3
77	Pharmacokinetics and bioavailability of marbofloxacin in lambs following administration of intravenous, intramuscular and subcutaneous. 2018 , 159, 5-10		4
76	Fiber enhanced Raman sensing of levofloxacin by PCF bandgap-shifting into the visible range. 2018 , 10, 586-592		19
75	A case of septicaemic melioidosis: Utility of therapeutic drug monitoring and high-dose meropenem in successful management. 2018 , 36, 597-599		1
74	Pharmacokinetics-pharmacodynamics issues relevant for the clinical use of beta-lactam antibiotics in critically ill patients. 2018 , 22, 233		69
73	Population Pharmacokinetics of Vancomycin in Patients Undergoing Allogeneic Hematopoietic Stem-Cell Transplantation. 2018 , 58, 1140-1149		10
72	Review of antimicrobial use and considerations in the elderly population. 2018 , 13, 657-667		24
71	Single-Center Pharmacokinetic Study and Simulation of a Low Meropenem Concentration in Brain-Dead Organ Donors. <i>Antimicrobial Agents and Chemotherapy</i> , 2018 , 62,	5.9	2
70	Drug-Induced Acute Kidney Injury. 2019 , 214-221.e2		2

69	Population Pharmacokinetic Analyses for Plazomicin Using Pooled Data from Phase 1, 2, and 3 Clinical Studies. <i>Antimicrobial Agents and Chemotherapy</i> , 2019 , 63,	5.9	12
68	LC-MS/MS method for simultaneous determination of linezolid, meropenem, piperacillin and teicoplanin in human plasma samples. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2019 , 169, 11-18	3.5	21
67	Future Challenges in Pediatric and Neonatal Sepsis: Emerging Pathogens and Antimicrobial Resistance. 2019 , 8, 17-24		17
66	Pharmacokinetic Study of Cefazolin in Short Daily Hemodialysis. 2019 , 53, 348-356		
65	The Role of Antibiotic Stewardship in Promoting Appropriate Antibiotic Use. 2019 , 13, 376-383		9
64	A critical review of HPLC-based analytical methods for quantification of Linezolid. 2020 , 50, 196-211		8
63	Evaluation of the Accuracy of Standard Renal Function Equations in Critically Ill Patients with Subarachnoid Hemorrhage. 2020 , 32, 828-835		1
62	A Retrospective Review of the Efficiency of First-Dose Therapeutic Drug Monitoring of Gentamicin, Amikacin, and Vancomycin in the Pediatric Population. 2020 , 60, 7-15		3
61	Caspofungin: a review of its characteristics, activity, and use in intensive care units. 2020 , 18, 1213-1220		9
60	Failure of target attainment of beta-lactam antibiotics in critically ill patients and associated risk factors: a two-center prospective study (EXPAT). 2020 , 24, 558		24
59	Antimicrobial Therapy in Septic Shock Is Conservative During Resuscitation and Maintenance Phases. 2020 , 36, 119-125		
58	Dosierung von Antiinfektiva bei intensivpflichtigen Patienten mit akutem Nierenversagen und Nierenersatztherapie. 2020 , 15, 225-232		1
57	Optimizing Antibiotic Treatment Strategies for Neonates and Children: Does Implementing Extended or Prolonged Infusion Provide any Advantage?. <i>Antibiotics</i> , 2020 , 9,	4.9	0
56	Pharmacists Knowledge About the Impact of Augmented Renal Clearance on Antimicrobial Dosing in Critically Ill Patients: A Cross-Sectional Study. 2020 , 9, 599-608		1
55	Teicoplanin and therapeutic drug monitoring: An update for optimal use in different patient populations. 2020 , 26, 900-907		5
54	Exposure Variability and Target Attainment of Vancomycin: A Systematic Review Comparing Intermittent and Continuous Infusion. <i>Therapeutic Drug Monitoring</i> , 2020 , 42, 381-391	3.2	1
53	Population pharmacokinetic modeling and clinical application of vancomycin in Chinese patients hospitalized in intensive care units. 2021 , 11, 2670		2
52	Carbapenem Therapeutic Drug Monitoring in Critically Ill Adult Patients and Clinical Outcomes: A Systematic Review with Meta-Analysis. <i>Antibiotics</i> , 2021 , 10,	4.9	2

51	The Minimum Inhibitory Concentration of Antibiotics: Methods, Interpretation, Clinical Relevance. 2021 , 10,		44
50	Third generation cephalosporins and piperacillin/tazobactam have distinct impacts on the microbiota of critically ill patients. 2021 , 11, 7252		1
49	Hypoalbuminemia as Surrogate and Culprit of Infections. 2021 , 22,		16
48	Continuous Infusion of Piperacillin/Tazobactam and Meropenem in ICU Patients Without Renal Dysfunction: Are Patients at Risk of Underexposure?. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 2021 , 46, 527-538	2.7	2
47	The Role of PK/PD Analysis in the Development and Evaluation of Antimicrobials. <i>Pharmaceutics</i> , 2021 , 13,	6.4	12
46	Optimizing Antimicrobial Drug Dosing in Critically Ill Patients. <i>Microorganisms</i> , 2021 , 9,	4.9	8
45	How Antibiotics Stewardship Can Be Safely Implemented in Patients with Septic Shock?. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2021 , 42, 689-697	3.9	0
44	Population pharmacokinetics of meropenem in critically ill infant patients. <i>International Journal of Infectious Diseases</i> , 2021 , 111, 58-64	10.5	2
43	Population pharmacokinetics and dosing considerations for the use of daptomycin in adult patients with haematological malignancies. <i>Journal of Antimicrobial Chemotherapy</i> , 2017 , 72, 2342-2350	5.1	17
42	Variability in plasma concentration of cefotaxime in critically ill patients in an Intensive Care Unit of India and its pharmacodynamic outcome: A nonrandomized, prospective, open-label, analytical study. <i>Journal of Pharmacology and Pharmacotherapeutics</i> , 2016 , 7, 15-21	0.2	3
41	Pharmacokinetics/Pharmacodynamics of caspofungin in plasma and peritoneal fluid of liver transplant recipients. <i>Antimicrobial Agents and Chemotherapy</i> , 2021 , AAC0118721	5.9	0
40	Methods for Implementing Antibiotic Control in the Intensive Care Unit. 2007 , 159-167		
39	Drug-Induced Acute Renal Failure. 2009 , 317-324		1
38	Principles of Pharmacodynamics and Pharmacokinetics of Drugs Used in Extracorporeal Therapies. 2009 , 1190-1194		
37	Drug Distribution: Is it a more Important Determinant of Drug Dosing than Clearance?. 2010 , 507-516		
36	Drug Distribution: Is it a more Important Determinant of Drug Dosing than Clearance?. <i>Yearbook of Intensive Care and Emergency Medicine</i> , 2010 , 507-516		
35	Insufficienza epatica acuta in terapia intensiva. 2011 , 37-61		
34	Antibacterial Distribution and Drug-Drug Interactions in Cancer Patients. 2011 , 443-454		1

33	Antimicrobials in Chemotherapy Strategy. 2011 , 921-929		
32	Acute Liver Failure in Intensive Care. 2012 , 35-58		
31	Analysis of Vancomycin Plasma Concentrations Following Initial Dosing in Critically Ill Patients. <i>Journal of Korean Society of Health-System Pharmacists</i> , 2014 , 31, 888-897	0	
30	Antibiotic and Antifungal Therapy in the ICU. 2018 , 373-389		1
29	Focus on antibiotics: use and misuse in the intensive care unit, and antibiotics monitoring. 2006 , 179-184		
28	Are β -lactam concentrations adequate in severe sepsis and septic shock in children?. <i>Therapie</i> , 2020 , 75, 633-640	3.8	1
27	Calculated parenteral initial treatment of bacterial infections: Infections of the kidneys and the genito-urinary tract. <i>GMS Infectious Diseases</i> , 2020 , 8, Doc12	0.9	
26	Mesenchymal Stem Cell-Derived Exosome Therapy of Microbial Diseases: From Bench to Bed.. <i>Frontiers in Microbiology</i> , 2021 , 12, 804813	5.7	1
25	Consensus guidelines for optimising antifungal drug delivery and monitoring to avoid toxicity and improve outcomes in patients with haematological malignancy and haemopoietic stem cell transplant recipients, 2021.. <i>Internal Medicine Journal</i> , 2021 , 51 Suppl 7, 37-66	1.6	11
24	Risk Factors Associated with Suboptimal Tobramycin Levels in the Medical Intensive Care Unit.. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 2022 , 47, 271	2.7	
23	Early Empirical Use of Broad-Spectrum Antibiotics in Sepsis. <i>Current Infectious Disease Reports</i> , 1	3.9	1
22	Ensuring target concentrations of antibiotics in critically ill patients through dose adjustment.. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2022 ,	5.5	0
21	Therapeutic Drug Monitoring of Antibiotics in Critically Ill Children: An Observational Study in a Pediatric Intensive Care Unit.. <i>Therapeutic Drug Monitoring</i> , 2022 , 44, 319-327	3.2	0
20	Population Pharmacokinetics of Caspofungin and Dose Simulations in Heart Transplant Recipients.. <i>Antimicrobial Agents and Chemotherapy</i> , 2022 , e0224921	5.9	
19	Ventilation. 277-287		
18	Pharmacology in children. 300-308		
17	Penetration of antibacterials into bone: what do we really need to know for optimal prophylaxis and treatment of bone and joint infections?. <i>Clinical Pharmacokinetics</i> , 2009 , 48, 125-7	6.2	4
16	Therapeutic Drug Monitoring of Antifungal Agents in Critically Ill Patients: Is There a Need for Dose Optimisation?. <i>Antibiotics</i> , 2022 , 11, 645	4.9	0

15	Pharmacokinetic and Pharmacodynamic considerations of antibiotics and antifungals in liver transplant recipients. <i>Liver Transplantation</i> ,	4.5	
14	Fabrication and stabilization of nanosilver using Houttuigniae for antibacterial and catalytic application. <i>International Journal of Environmental Analytical Chemistry</i> , 1-21	1.8	○
13	High-throughput analysis for the simultaneous quantification of nine beta-lactam antibiotics in human plasma by UPC2-MS/MS: Method development, validation, and clinical application. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2022 , 219, 114904	3.5	○
12	Population pharmacokinetics of apramycin from first-in-human plasma and urine data to support prediction of efficacious dose. <i>Journal of Antimicrobial Chemotherapy</i> ,	5.1	1
11	Population-Based Pharmacokinetics and Dose Optimization of Imipenem in Vietnamese Critically-Ill Patients. Volume 15, 4575-4583		
10	HIPERFILTRACI3N GLOMERULAR EN EL PACIENTE TRAUM3TICO GRAVE. 2022 ,		
9	Grand challenge in antibiotic pharmacology: A major step toward tailored antimicrobial treatment in very complex clinical scenarios of infectious risk management. 1,		○
8	Optimizing Meropenem in Highly Resistant Klebsiella pneumoniae Environments: Population Pharmacokinetics and Dosing Simulations in Critically Ill Patients.		○
7	Reducing Toxicity in Critically Ill Patients by Using Therapeutic Drug Monitoring. 2022 , 143-160		○
6	The recommended dosage regimen for caspofungin in patients with higher body weight or hypoalbuminaemia will result in low exposure: Five years of data based on a population pharmacokinetic model and Monte-Carlo simulations. 13,		○
5	Acute Liver Failure: Definition, Epidemiology and Management [Update 2022]. 2022 , 19-47		○
4	The BloodBrain Barrier and Pharmacokinetic/Pharmacodynamic Optimization of Antibiotics for the Treatment of Central Nervous System Infections in Adults. 2022 , 11, 1843		○
3	Evaluation of continuous ampicillin/sulbactam infusion in critically ill patients. 2023 , 320, 121567		○
2	No evidence for relevant impact of renal replacement therapy on clinical effect of erythromycin in critically ill patients with sepsis. 2023 , 27,		○
1	Update on Therapeutic Drug Monitoring of Beta-Lactam Antibiotics in Critically Ill Patients [Narrative Review]. 2023 , 12, 568		○